JP2021526796A5 - - Google Patents
Info
- Publication number
- JP2021526796A5 JP2021526796A5 JP2020567764A JP2020567764A JP2021526796A5 JP 2021526796 A5 JP2021526796 A5 JP 2021526796A5 JP 2020567764 A JP2020567764 A JP 2020567764A JP 2020567764 A JP2020567764 A JP 2020567764A JP 2021526796 A5 JP2021526796 A5 JP 2021526796A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutically acceptable
- antisense oligomer
- acceptable salt
- oligomer according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024096569A JP2024116362A (ja) | 2018-06-13 | 2024-06-14 | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684615P | 2018-06-13 | 2018-06-13 | |
| US62/684,615 | 2018-06-13 | ||
| US201962860446P | 2019-06-12 | 2019-06-12 | |
| US62/860,446 | 2019-06-12 | ||
| PCT/US2019/036764 WO2019241385A2 (en) | 2018-06-13 | 2019-06-12 | Exon skipping oligomers for muscular dystropy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024096569A Division JP2024116362A (ja) | 2018-06-13 | 2024-06-14 | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021526796A JP2021526796A (ja) | 2021-10-11 |
| JP2021526796A5 true JP2021526796A5 (cg-RX-API-DMAC7.html) | 2022-06-13 |
Family
ID=68843196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567764A Withdrawn JP2021526796A (ja) | 2018-06-13 | 2019-06-12 | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
| JP2024096569A Pending JP2024116362A (ja) | 2018-06-13 | 2024-06-14 | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024096569A Pending JP2024116362A (ja) | 2018-06-13 | 2024-06-14 | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20220251551A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021526796A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019241385A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US20250228954A1 (en) * | 2020-01-24 | 2025-07-17 | Sarepta Therapeutics, Inc. | Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning |
| PE20230237A1 (es) | 2020-02-28 | 2023-02-07 | Nippon Shinyaku Co Ltd | Acidos nucleicos antisentido que inducen la omision del exon 51 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3978608A1 (en) * | 2020-10-05 | 2022-04-06 | SQY Therapeutics | Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51 |
| CN118401553A (zh) * | 2021-07-09 | 2024-07-26 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| AU2023245901A1 (en) * | 2022-03-30 | 2024-10-03 | Biomarin Pharmaceutical Inc. | Dystrophin exon skipping oligonucleotides |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627917T3 (es) * | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| NZ584793A (en) * | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| WO2009101399A1 (en) * | 2008-02-12 | 2009-08-20 | Isis Innovation Limited | Treatment of muscular dystrophy using peptide nucleic acid ( pna) |
| EP3133160B1 (en) * | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| SI2607484T1 (sl) * | 2008-10-27 | 2016-11-30 | Biomarin Technologies B.V. | Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije |
| CN102459595A (zh) * | 2009-04-24 | 2012-05-16 | 普罗森那技术公司 | 用于治疗dmd的包含肌苷的寡核苷酸 |
| HUE040445T2 (hu) * | 2009-11-12 | 2019-03-28 | Univ Western Australia | Antiszensz molekulák és eljárások betegségek kezelésére |
| BR112013020273A2 (pt) * | 2011-02-08 | 2016-10-18 | Charlotte Mecklenburg Hospital | oligonucleotídeos antissenso |
| AU2011367230B2 (en) * | 2011-05-05 | 2017-08-10 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CA2862628C (en) * | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| US9217148B2 (en) * | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| HK1220154A1 (zh) * | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| JP2018530560A (ja) * | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス, インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
| MA45158A (fr) * | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Composition pharmaceutique comprenant de l'éteplirsen |
| US20190330626A1 (en) * | 2016-07-15 | 2019-10-31 | Ionis Pharmaceuticals, Inc. | Compounds and methods for use in dystrophin transcript |
| GB201711809D0 (en) * | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
-
2019
- 2019-06-12 US US16/973,464 patent/US20220251551A1/en not_active Abandoned
- 2019-06-12 JP JP2020567764A patent/JP2021526796A/ja not_active Withdrawn
- 2019-06-12 WO PCT/US2019/036764 patent/WO2019241385A2/en not_active Ceased
-
2024
- 2024-06-14 JP JP2024096569A patent/JP2024116362A/ja active Pending
-
2025
- 2025-03-05 US US19/071,514 patent/US20250290069A1/en active Pending